Week 5 CARDIOVASCULAR: HTN/HEART FAILURE Flashcards
Pharmacologic treatment for HTN is indicated for primary prevention
No CVD, 10 year ASCVD <10%, and SBP >=140 or DBP >=90 OR NoCVD, 10 year ASCVD >=10% and SBP >=130 or DBP >=80
First line pharmaceutical options for treatment of HTN
Diuretics, ACE inhibitors, ARBs, CCB
Class of antihypertensive drug that should be used with caution in individuals with gout
Thiazide diuretics
Pharmacologic agent that prevents conversion of Angiotensin 1 to Angiotensin II
ACE inhibitor
Antihypertensive of choice (2) in the black population
Thiazide diuretics and CCB
Antihypertensive of choice for individuals with CKD
ACE inhibitor (or ARB if not tolerated)
Side effect of ACE inhibitors related to blocking of bradykinase
cough
Mechanism of Action: ARB
Blocks access of angiotensin II
Mechanism of Action: CCB
Blocks calcium influx resulting in vasodilation
Block only Beta receptors in heart and kidneys
Cardio-selective Beta Blocker
Class of antihypertensive that should be used cautiously in individuals with lung disease
Non selective beta blocker
Class of antihypertensive that has a common side effect of orthostatic hypotension
Alpha blockers
Hypertension caused by a co-morbid condition or drug
Secondary Hypertension
Cornerstone of treatment of HF
Ace inhibitors and beta blockers
Drugs routinely used in addition to ACEI and Beta blockers in HFREF (Stage C)
Diuretics (loop) and Aldosterone antagonist (spironolactone)
Goal in dosing ACE inhibitors in HF
Maximal dose tolerated
Medication class that minimizes cardiac remodeling
ACE inhibitors
Goals of treatment of HF (Stage A)
Healthy lifestyle, prevent vascular/coronary disease, prevent LV structural abnormalities
Class of diuretic most commonly used to treat HF
Loop diuretics (e.g. furosemide, bumetanide)
Common OTC analgesic that interacts with loop diuretic
NSAIDS